Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
The Departments of Labor, Health and Human Services, and the Treasury May 15 announced that they will not enforce the 2024 mental health parity final rule, a…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
Beth Heinz, senior vice president, Women’s and Children’s Services at Yale New Haven Health, and Cheri Johnson, chief nursing officer, Woman’s Hospital in…
Headline
Zaira Khalid, M.D., senior staff geriatric psychiatrist at Henry Ford Behavioral Health Hospital, discusses the unique physical, emotional and social needs of…
Headline
A new initiative launched March 18 by the Dr. Lorna Breen Heroes' Foundation seeks to improve mental health care access for health care workers. The program,…
Headline
A study published Feb. 26 by JAMA Psychiatry found that female physicians died by suicide at more than 1.5 times the rate of female nonphysicians from 2017-…